Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.

Capoor, Malini R.; Nair, Deepthi; Posti, Jitendra; Singhal, Smita; Deb, Monorama; Aggarwal, Praveen; Pillai, Parukutty

doi:10.1099/jmm.0.47853-0

Cited by 32 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If combined resistance to all first-and second-line drugs develops, the carbapenems (e.g., imipenem, meropenem, and ertapenem), and tigecycline could be potential alternatives (571). There are few reports describing the use of these potentially expensive drugs (572).…”

Section: Carbapenems and Tigecyclinementioning

confidence: 99%

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections

et al. 2015

View full text Add to dashboard Cite

SUMMARY Salmonella enterica infections are common causes of bloodstream infection in low-resource areas, where they may be difficult to distinguish from other febrile illnesses and may be associated with a high case fatality ratio. Microbiologic culture of blood or bone marrow remains the mainstay of laboratory diagnosis. Antimicrobial resistance has emerged in Salmonella enterica , initially to the traditional first-line drugs chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole. Decreased fluoroquinolone susceptibility and then fluoroquinolone resistance have developed in association with chromosomal mutations in the quinolone resistance-determining region of genes encoding DNA gyrase and topoisomerase IV and also by plasmid-mediated resistance mechanisms. Resistance to extended-spectrum cephalosporins has occurred more often in nontyphoidal than in typhoidal Salmonella strains. Azithromycin is effective for the management of uncomplicated typhoid fever and may serve as an alternative oral drug in areas where fluoroquinolone resistance is common. In 2013, CLSI lowered the ciprofloxacin susceptibility breakpoints to account for accumulating clinical, microbiologic, and pharmacokinetic-pharmacodynamic data suggesting that revision was needed for contemporary invasive Salmonella infections. Newly established CLSI guidelines for azithromycin and Salmonella enterica serovar Typhi were published in CLSI document M100 in 2015.

show abstract

Section: Carbapenems and Tigecyclinementioning

confidence: 99%

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Carbapenems have been reported to be active against Salmonella species in vitro (3). However, clinical data regarding the use of carbapenems in the treatment of invasive Salmonella infections are limited.…”

mentioning

confidence: 99%

Use of Carbapenems against Clinical, Nontyphoid Salmonella Isolates: Results from In Vitro and In Vivo Animal Studies

Tang

Chen

Zhang

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

fThe emergence of multidrug-resistant Salmonella isolates has created the need for new therapeutic agents. We evaluated the intracellular activity of four carbapenem compounds against clinical nontyphoid Salmonella (NTS) isolates in vitro and ex vivo. Subsequently, the efficacy of carbapenem treatment against selected Salmonella isolates in vivo was assessed using a murine peritonitis model. The MIC 50 and MIC 90 for doripenem, ertapenem, imipenem, and meropenem against 126 NTS isolates were found to be 0.062 and 0.062, 0.015 and 0.015, 0.5 and 1, and 0.031 and 0.031 g/ml, respectively. The intracellular killing effect of ertapenem was sustained for 24 h and was superior to that of imipenem, meropenem, and doripenem; its effect was comparable to that of ceftriaxone. Ertapenem demonstrated an excellent pharmacokinetic profile with a percent time above the MIC of 75.5% and an area under the concentration-time curve/MIC ratio of 20,733. When peritoneal exudate cells were examined directly ex vivo from mice with Salmonella-induced peritonitis, cells from mice treated with ertapenem and ceftriaxone had intracellular and extracellular bacterial counts reduced 10 2 -to 10 4 -fold and exhibited killing effects similar to each other. The survival rates of mice inoculated with 1 ؋ 10 5 and 10 6 CFU of a ceftriaxone-susceptible Salmonella isolate that were subsequently treated with ertapenem or ceftriaxone were 100% and 90%, respectively. When mice were inoculated with 5 ؋ 10 4 and 10 5 CFU of a ceftriaxone-resistant and ciprofloxacin-resistant Salmonella isolate, mice treated with ertapenem had a higher survival rate than mice treated with ceftriaxone (70% versus 0% and 50% versus 0%, respectively; P < 0.001). Our results suggest that ertapenem is at least as effective as ceftriaxone in treating murine Salmonella infections and show that further clinical investigations on the potential use of ertapenem in treatment of human Salmonella infections are warranted.

show abstract

“…16 The majority of Salmonella strains isolated from the Indian subcontinent now have MICs .0.12 mg/l for ciprofloxacin. 17 Suggested alternatives for fluoroquinolone resistant strains have included ampicillin, chloramphenicol, trimethoprim-sulphamethoxazole, third generation cephalosporins and azithromycin. 11,13 Several studies have confirmed the usefulness of azithromycin in the treatment of multi-drug resistant, nalidixic acid resistant enteric fever.…”

Section: Discussionmentioning

confidence: 99%

Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused bySalmonella entericaserotype Paratyphi A

Fernando

Molland

Gottlieb

2012

Pathogens and Global Health

View full text Add to dashboard Cite

show abstract

Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.

Cited by 32 publications

References 23 publications

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections

Use of Carbapenems against Clinical, Nontyphoid Salmonella Isolates: Results from In Vitro and In Vivo Animal Studies

Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused bySalmonella entericaserotype Paratyphi A

Contact Info

Product

Resources

About